| Verified against primary record | |
| European activity | 910,470 treatment cycles reported from 34 countries, reference year 2021[1] |
|---|---|
| Cross-border field | None; the registry system carries no foreign-patient flag[1] |
| Eligibility law | In 11 of 43 European countries access was limited to heterosexual couples with an infertility diagnosis, at 31 December 2018[2] |
| Records read | Registry aggregation and regulator guidance, 30 September 2026 |
| Independently reported | |
| Donor traceability | Anonymity rules differ between countries and follow the country of treatment[3] |
| Bands apply only to the rows beneath them. The registry covers 81.4 per cent of clinics in participating countries, so its total is a floor. | |
Fertility tourism, more precisely called cross-border reproductive care, is travel to obtain assisted reproduction in another country. It is driven less by price than by law: what a clinic may do, and for whom, is set nationally, and those rules diverge sharply within a single continent.
The scale of the activity, and the hole in the middle of it
Europe has the most complete assisted reproduction dataset anywhere. Preliminary results from the European registry consortium for reference year 2021 cover 34 countries and 1,155 participating clinics, being 81.4 per cent of registered clinics in those countries, plus 1,242 intrauterine insemination units. They record 910,470 treatment cycles in total: 346,183 cycles of intracytoplasmic sperm injection, 311,487 frozen embryo transfers, 115,567 conventional in vitro fertilisation cycles, 69,883 egg donation cycles and 62,694 cycles involving preimplantation genetic testing.[1]
That dataset contains no cross-border or foreign-patient data at all. This is the central measurement problem of the subject: the largest and most recent European collection has no field for the thing this entry is about. Any claim that a given percentage of European fertility care is cross-border cannot be checked against it, and must be traced to its own, older and smaller, source.
The figures that do exist are dated. An institutional fact sheet published in January 2017 put cross-border patients at approximately 5 per cent of all fertility care in Europe, based on surveys over ten years and with no reference year for the figure itself, at almost 3 per cent of United States cycles in 2013, and at 8.5 per cent of all fertility treatments in Spain in 2014, of which 66 per cent were egg donation.[4]
Why patients travel
Eligibility is the first reason. A survey published in February 2020, with data accurate as at 31 December 2018, covered 43 European countries and found 41 with statutory regulation of assisted reproduction. In 11 of the 43, access was limited to heterosexual couples with a diagnosis of infertility, which the survey states precludes treatment of single and lesbian women.[2] It does not follow that the remaining 32 permitted such treatment; the survey reports only the restrictive group, and a country outside it may restrict access by other means.
Beyond eligibility, the same institutional fact sheet gives four reasons for travel: legal restriction at home, waiting lists, lower cost, and a preferred legal framework such as donor anonymity.[4]
What follows the child, not the patient
The British fertility regulator sets out the consequences of treatment abroad more clearly than most sources, and the striking feature is that the most durable ones fall on the child rather than the patient. Some jurisdictions permit anonymous donation, meaning a donor-conceived person would have no way to trace their donor; under British law they may obtain non-identifying details at 16 and identifying information at 18. British law also limits one donor’s gametes to up to 10 families, which limits how many children a given child may be genetically related to, whereas other countries may set no such limit. Overseas clinics may not follow single embryo transfer practice, and the regulator advises asking about a clinic’s multiple birth rate, noting that twin and triplet pregnancies are the single biggest risk to the health of mothers and babies.[3]
On its own reach the regulator is blunt: fertility treatment is not regulated in the same way outside the country, not all countries have laws governing treatment, it has no powers overseas, and it cannot deal with a complaint about treatment carried out abroad.[3] That guidance was last reviewed in 2016, and the domestic rules it describes should be checked against current law.
See also
- Surrogacy abroad, the adjacent field where parentage rather than treatment is the legal problem
- Medical travel for LGBTQ+ patients, where these eligibility rules bite hardest
- Medical travel for unavailable treatments, the broader category of law-driven travel
- Abortion travel, the other reproductive field where law sets the border
References
- European IVF-monitoring Consortium, European Society of Human Reproduction and Embryology. Assisted Reproductive Technology in Europe 2021: preliminary results generated from European registers. Human Reproduction, vol. 39, supplement 1, July 2024; reference year 2021. Verified against primary record: registry aggregation, published as a conference abstract with preliminary results. Retrieved 30 September 2026.
- European Society of Human Reproduction and Embryology. Europe moves towards complete statutory regulation of assisted reproduction but large variations still exist in how the legislation is applied. Published 6 February 2020; data accurate as at 31 December 2018. Verified against primary record: the society’s own publication of its survey. Retrieved 30 September 2026.
- Human Fertilisation and Embryology Authority. Fertility treatment abroad. Page last reviewed 14 July 2016. Verified against primary record: statutory regulator guidance opened and read. Retrieved 30 September 2026.
- European Society of Human Reproduction and Embryology. Fact sheet: Cross border reproductive care. Dated 1 January 2017, with underlying figures from 2013 and 2014. Verified against primary record: institutional publication opened and read. Retrieved 30 September 2026.
Sourcing note: the registry publication, the eligibility survey, the regulator guidance and the fact sheet were opened and read on 30 September 2026. The 2021 registry figures are preliminary results published as a conference abstract and may be superseded by a final report. The frequently quoted estimate of 11,000 to 14,000 cross-border fertility patients a year is not used here, because it is an extrapolation from a one-month questionnaire snapshot at 46 clinics in six countries in 2008 and 2009. The regulator guidance dates from 2016 and the domestic rules it describes require re-checking.